TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06370910

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-Level Laser Therapy
Description: The patient will be submitted to evaluation through a questionnaire, which will be the patient's evaluation form, which will be elaborated by the researcher (Appendix A). Next, pain and edema will be evaluated, using the VAS scales, Mc Gill scale and REEDA scale, after this process, the therapy will be applied, and the patient will be randomly selected for cryotherapy or LLLT. After application, the patient will be evaluated immediately and the scales applied again and after 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-Level Laser Therapy
Description: The patient will be submitted to evaluation through a questionnaire, which will be the patient's evaluation form, which will be elaborated by the researcher (Appendix A). Next, pain and edema will be evaluated, using the VAS scales, Mc Gill scale and REEDA scale, after this process, the therapy will be applied, and the patient will be randomly selected for cryotherapy or LLLT. After application, the patient will be evaluated immediately and the scales applied again and after 24 hours.
Study: NCT06333691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Gluconate
Description: to compare the effectiveness of calcium gluconate, cabergoline and diosmin in preventing ovarian hyperstimulation syndrome in high-risk patient undergoing ICSI procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Gluconate
Description: to compare the effectiveness of calcium gluconate, cabergoline and diosmin in preventing ovarian hyperstimulation syndrome in high-risk patient undergoing ICSI procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Gluconate
Description: to compare the effectiveness of calcium gluconate, cabergoline and diosmin in preventing ovarian hyperstimulation syndrome in high-risk patient undergoing ICSI procedure.
Study: NCT05154383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)
Description: Patient will received one dose of High Dose Quadrivalent Influenza Vaccine according to marketing authorization.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine
Description: Patient will received one dose of Standard Dose Quadrivalent Influenza Vaccine according to marketing authorization.
Study: NCT05064852

Intervention type: DRUG
Intervention: Surufatinib
Description: The study is a real-world study. According to the actual medical history of patients, the usage of Surufatinib was collected.
Study: NCT05699330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral subgenual cingulate deep brain stimulation (SGC DBS)
Description: Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone. All patients will receive deep brain stimulation (DBS) targeting the subgenual cingulate (SGC) bilaterally. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
Study: NCT06276933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab + chemotherapy+Thalidomide
Description: Camrelizumab + chemotherapy+Thalidomide Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210~Drug: Thalidomide Thalidomide 100mg，po qd； Other Name: Thalidomide~Drug: Chemotherapy~Platinum-based chemotherapy:~Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD; Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.~Other Name: Platinum-based chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab + chemotherapy+placebo
Description: Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210~Drug: placebo 100mg placebo 100mg，po qd；~Drug: Chemotherapy~Platinum-based chemotherapy:~Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD; Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.~Other Name: Platinum-based chemotherapy
Study: NCT04756557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental.
Description: Tooth Brushing HAP 2x daily repeated cleaning of all teeth 3 min. using a standardized electric tooth brush Electric (powered) toothbrushes (Oral-B; P\&G, Schwalbach, Germany), brushing head: medium; will be changed every 2 months and a non-fluoridated tooth paste containing microcrystalline hydroxyapatite . HAP-toothpaste (Karex toothpaste with 10 % hydroxyapatite) If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexi-dine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Tooth Brushing F 2x daily repeated cleaning of all teeth 3min.using a standardized electric tooth brush ((Oral-B; P\&G, Schwalbach, Germany) and a fluoridated toothpaste (Karex Base with sodium fluoride 1450 F-), brushing head: medium; will be changed every 2 months If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexidine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
Study: NCT04749732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WalkingPad plus Psychological Intervention - PsyWPad Group
Description: The 24-week walking program will be monitored by the WalkingPAD application that will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Transtheoretical Model of Change and the Theory of Planned Behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WalkingPad plus Virtual Assistant - CyberWPad Group
Description: The 24-week walking program will be monitored by the WalkingPAD application, which will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support will be provided by a virtual assistant through daily and on-the-spot interactions and through support and motivational messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WalkingPad group - Paper WPad Group
Description: The 24-week walking program will be supported by a printed prescription of an individualized HbET previously defined on the WalkingPAD platform. However, this group of patients will not have the support of an application to monitor and record adherence to the program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Trans-Theoretical Model of Change and the Theory of Planned Behavior.
Study: NCT06231238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Acceptance and Commitment Therapy
Description: Balance-ACT is an ACT-based psychological intervention specifically designed for people with PCS/LC. Balance-ACT will use ACT techniques and mindfulness and will focus on establishing a balance psychologically and physiologically and regulating homeostasis. More specifically, Balance ACT will aim to regulate behaviours such as sleep, stress and activity, which can subsequently have an impact on homeostasis and physiology. Balance-ACT will also encourage people to live a values-based life and set goals according to their values.
Study: NCT04000841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful You mobile app
Description: The CRSR intervention consists of a native mobile application for Android and iOS devices. The mobile app includes:~* Guided meditations of varying length designed to connect the user to the present moment and a place of calm through culturally aligned exercises grounded in spirituality, orality, self-empowerment, and resilience.~* User-customized notifications prompting users to reflect and engage with the app, such as providing African American proverbs and quotes and asking simple questions like What are you grateful for today?~* Scheduled messages on the importance mindfulness as a way increase control over physical and psychological health~* User-customized reminders to do specific meditations and display personally selected images or messages.
Study: NCT05387824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation -Armchair type MS • NovaMag NT-60
Description: MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation- TTNS
Description: TTNS were performed 2 days a week, for 30 min a day, for a total of 12 sessions for 6 weeks.
Study: NCT05766059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: The standard PAS protocol will be compared with the mirrorPAS protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: The standard PAS protocol will be compared with the mirrorPAS protocol.
Study: NCT05751980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Med Wise Rx
Description: The program consists of two 120-minute classes led by trained community site-based facilitators, designed to help older adults communicate more effectively with their pharmacists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Med Wise Rx
Description: The program consists of two 120-minute classes led by trained community site-based facilitators, designed to help older adults communicate more effectively with their pharmacists.
Study: NCT06459414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: : Oropharyngeal Administration Of Colostrum
Description: Preterm less than 34 weeks gestation will receive Oropharyngeal Colostrum for 3 days ( the first group) and for 10 days( the second group)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: : Oropharyngeal Administration Of Colostrum
Description: Preterm less than 34 weeks gestation will receive Oropharyngeal Colostrum for 3 days ( the first group) and for 10 days( the second group)
Study: NCT06576557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KNEE-DEeP intervention- Knowledge translation and exercise for early degenerative knee pain
Description: The intervention for health care professionals (GPs and physiotherapists) will consist of training and education. The two-hour educational workshop for GPs will focus on diagnosis and management of patients with early degenerative knee pain, and enhancing communication skills. Training for physiotherapists will focus on delivery of a 'best practice' session. The patient participant intervention will consist of an 'enhanced consultation' delivered by the GP. This will involve a physical exam, key educational messages, written information and a treatment plan. Patients will receive a single session of physiotherapy within 2 weeks of referral from their GP. This 'best practice' session will focus on self-management skills, targeted patient education, goal setting, action planning and exercise prescription.
Study: NCT06640257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314 injection
Description: SHR-1314 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1314 injection
Description: SHR-1314 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05387824

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Training
Description: Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.~BT, consisting of four stages, did not contain any PFMT programs in two groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Training
Description: Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.~BT, consisting of four stages, did not contain any PFMT programs in two groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Training
Description: Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.~BT, consisting of four stages, did not contain any PFMT programs in two groups.
Study: NCT05676580

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cross-linking surgery or intra corneal ring
Description: After keratoconus diagnosis the patient was assigned to surgery

Intervention type: OTHER
Group type: OTHER
Intervention: abstention
Description: No surgery
Study: NCT04591028

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine green
Description: A one time injection of IDC prior to the day of scheduled surgery.
Study: NCT05195905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMEG
Description: All devices that will be modified in this study protocol are commercially available in the United States. The commercially available endografts will be used to construct a fenestrated/branched device for this intervention.
Study: NCT05263271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentulizumab
Description: Gentulizumab will be administered by intravenous infusion once a week, with every 28 days as a dosing cycle .
Study: NCT05719883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maurora® Sirolimus Eluting Stent System
Description: The Maurora® for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APOLLO™ Intracranial Stent System
Description: The Apollo stent system comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
Study: NCT05569668

Intervention type: DRUG
Intervention: Paclitaxel- and platinum-based chemotherapy
Description: Neoadjuvant Chemotherapy
Study: NCT06017297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg via intravenous (IV) infusion every 3 weeks for up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: A single dose of tremelimumab at 300mg IV is given on C1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is dosed at 1000 mg/m2 IV on day (D)1 and D8 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is dosed at 25mg/m2 on D1 and D8 of each cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: If the tumor is evaluated to be resectable (as defined as successfully treated stage II (tumor shrink away from vessels), stage IIIA (tumor shrink away from visceral peritoneum), stage IIIB (N1 disease no longer pathologically enlarged) after C4 or C8, then the patient may proceed with surgical tumor resection.
Study: NCT05864079

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: Platelet count in study groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: Platelet count in study groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: Platelet count in study groups
Study: NCT05849779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled sedation with sevoflurane
Description: In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous sedation (current practice)
Description: In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP).
Study: NCT05226182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visualisation of a digital care path
Description: The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team. The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records. The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement. Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visualisation of a digital care path
Description: The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team. The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records. The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement. Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
Study: NCT05180266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form, PSQI,MRS and MENQOL. After pre-test data collection, women will be given an appointment for therapeutic administration.The therapeutic touch group will be applied to the therapeutic touch group once a week for four weeks in a suitable room in the Faculty of Nursing and on the specified day and time by the researcher.At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Listening Group
Description: Each of the women was informed about the purpose and content of the study at the first meeting, and informed consent was obtained from the women who met the conditions for participation and accepted to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. Music stream, music will be uploaded to mobile phones. He will be asked to listen to music (relaxation music in the relaxation exercises CD prepared by the Turkish Psychological Association) for 30 minutes before going to sleep every day for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. No action will be taken on the control group for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
Study: NCT06311760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0292
Description: AZD0292 will be administered as single dose via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0292
Description: AZD0292 will be administered as single dose via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0292
Description: AZD0292 will be administered as single dose via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as IV infusion.